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ABSTRACT 
 
Multibillion-clone landscape phage display libraries were 
prepared by the fusion of the phage major coat protein 
pVIII with foreign random peptides. Phage particles and 
their proteins specific for cancer and bacterial cells were 
selected from the landscape libraries and exploited as 
molecular recognition interfaces in detection, gene- and 
drug-delivery systems. The biorecognition interfaces 
were obtained by incorporation of the cell-specific phage 
fusion proteins into liposomes using intrinsic structural 
duplicity of the proteins. As a paradigm, we incorporated 
targeted pVIII proteins into commercially available 
therapeutic liposomes “Doxil”, which acquired a new 
emergent property—ability to bind target receptors. 
Targeting of the drug was evidenced by fluorescence-
activated cell sorting, microarray, optical and electron 
microscopy. In contrast to a poorly controllable 
conjugation targeting, the new landscape phage-based 
approach relies on very powerful and extremely precise 
mechanisms of selection, biosynthesis and self assembly, 
in which phages themselves serve as a source of the final 
product. 
 
1. INTRODUCTION 
 
Phage display technology emerged as a synergy of two 
fundamental concepts: combinatorial peptide libraries 
and fusion phage.  The first concept replaced the 
traditional collections of natural or individually 
synthesized compounds for libraries of peptides obtained 
in parallel synthesis as grouped mixtures [1, 2] (reviewed 
in [3]); the second—allowed displaying foreign peptides 
on the surface of bacterial viruses (bacteriophages) as part 
of their minor or major coat proteins [4, 5](reviewed in 
[6, 7]).  The merge of these two concepts resulted in 
development of phage display libraries—multibillion 
clone compositions of self-amplified and self-assembled 
biological particles [6].  In particular, a paradigm of 
landscape phage libraries evolved, in which the phage is 
considered not just as a genetic carrier for foreign 
peptides, like in the traditional phage display approach, 
but rather as a nanoparticle (nanotube) with emergent 
physico-chemical characteristics determined by specific 
phage landscapes formed by thousands of random 
peptides fused to the major coat protein pVIII [8].  These 
constructs display the guest peptide on every pVIII 
subunit increasing the virion’s total mass by 10%.  
Despite of the extra burden, such particles could retain 
their infectivity and progeny-forming ability.   
There is a fast growing interest to the landscape 
phages as a new type of selectable nanomaterials.  The 
landscape phage can bind organic ligands, proteins and 
antibodies [8, 9], induce specific immune responses in 
animals [10-13], or resist stress factors such as 
chloroform or high temperature [8, 14].  Landscape 
phages have been shown to serve as substitutes for 
antibodies against cell-displayed antigens and receptors 
[15-20], diagnostic probes for bacteria and spores [21-
24], gene- and drug-delivery systems [20, 25], and 
biospecific adsorbents [26]. Phage-derived probes inherit 
the extreme robustness of wild-type phage [14] and allow 
fabrication of bioselective materials by self-assemblage of 
phage or its composites on metal, mineral or plastic 
surfaces [24, 27-32]. Landscape phages specific for 
bacterial cells and spores have been exploited as 
molecular recognition interfaces in detection systems [27, 
33].  
 In this report we first demonstrate the use of the 
landscape phage as a bioselective interface in drug 
delivery systems. The concept of using targeted 
pharmaceutical nanocarriers to enhance the efficiency of 
anti-cancer drugs has been proven over the past decade 
both in pharmaceutical research and clinical setting. 
Examples of a successful realization of this concept are 
listed in numerous reviews, for example [34-37].  In 
particular, it is commonly accepted that selectivity of 
drug delivery systems can be increased by their coupling 
with peptide and protein ligands targeted to differentially 
expressed receptors (reviewed in [38-40]). The 
abundance of these receptors was demonstrated recently 
by comparative analysis of gene expression in tumor cells 
and tumor vascular endothelial cells versus adjacent 
normal tissues   [41], and their targeting is turning into a 
routine procedure in the most advanced laboratories due 
to the progress in combinatorial chemistry and phage 
display (a long lists of different target-specific peptides 
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identified by phage display  can be found in recent 
reviews [6, 39, 43-45].  In particular, selection protocols 
were developed for obtaining the phages and peptides 
internalizing into cancer cells [19, 46-50], and phage 
homing at tumors of human patients [51]  
A new challenge, within the frame of this 
concept, is to develop highly selective, stable, active and 
physiologically acceptable ligands that would navigate 
the encapsulated drugs to the site of the disease and 
control unloading of their toxic cargo inside the cancer 
cells. We have shown earlier that the tumor-specific 
peptides fused to the major coat protein pVIII can be 
affinity selected from multibillion clone landscape phage 
libraries by their ability to bind very specifically cancer 
cells [16, 19]. Here we show that the target-specific 
phage can be converted easily into the drug-loaded 
vesicles in which the fusion phage proteins span the lipid 
bilayer of liposomes or micelles and display the target-
binding peptides on the surface of the vesicles, as 
illustrated in Fig.1. Thus, the major principle of our 
approach is that targeted drug-loaded nanoparticles 
recognize the same receptors, cells, tissues and organs 
that have been used for selection of the precisely targeted 
landscape phage. 
 
2. LANDSCAPE PHAGE LIBRARIES AS A 
SOURCE OF BIOSELECTIVE PROBES 
 
The filamentous bacteriophages Ff (fd, f1 and M13) are 
long, thin viruses, which consist of a single-stranded 
circular DNA packed in a cylindrical shell composed of 
the major coat protein pVIII (98% of the total protein 
mass), and a few copies of the minor coat proteins 
capping the ends of the phage particle (Fig. 2). Foreign 
peptides were displayed on the pVIII protein [5] soon 
after the display on the minor coat protein pIII was 
pioneered (reviewed in [7]). The pVIII-fusion phages 
display the guest peptide on every pVIII subunit, 
increasing the virion’s total mass by up to 15%. Such 
particles were given the name “landscape phage” to 
emphasize the dramatic change in surface architecture 
caused by arraying thousands of copies of the guest 
peptide in a dense, repeating pattern around the tubular 
capsid, as illustrated by Fig. 3 [8]. It was shown that the 
foreign peptides replacing three or four mobile amino 
acids close to the N-terminus of the wild-type protein 
pVIII don’t disturb considerably the general architecture 
of virions and don’t change the conformation of the 
fusion proteins in membranes [13, 52, 53]. A landscape 
library is a diverse population of phages, encompassing 
billions of clones with different surface structures and 
biophysical properties [7]. Therefore, the landscape phage 
is unique micro-fibrous material that can be selected in 
the affinity binding protocol and obtained by a routine 
and simple microbiological procedure. Binding peptides, 
8-9 amino acid long, comprising up to 20% of the phage 
mass may be easily prepared by cultivation of the infected 
bacteria and isolation of the secreted phage particles by 
precipitation. Landscape phages have been shown to 
serve as substitutes for antibodies against various 
antigens and receptors, including live cancer and bacterial 
cells, in gene-delivery vehicles, and as analytical probes 
in biosensors. Although phages themselves are very 
attractive bioselective materials, alternative targeted 
forms containing phage proteins may be more 
advantageous in medical applications where 
nanoparticulate materials are required, such as 
bioselective drug delivery liposomes described below. 
 
Fig. 2. Filamentous phage.  Left: electron 
micrograph.  The aminoterminus of pIII proteins 
are pointed by arrow. Right: Segment of ~1% of 
phage virion with the array of the pVIII proteins 
shown as electron densities (Micrograph and 
model courtesy of Gregory Kishchenko) 
 
Fig. 3. Structure of 
landscape phage.  
Foreign peptides are 
pictured with dark 
atoms; their overall 
arrangement corres-
ponds to the model of 
Marvin, 1994.  
Fig.1. Drug-loaded liposome targeted by the 
pVIII protein.  The hydrophobic helix of pVIII 
spans the lipid layer and binding peptide is 
displayed on the surface of the carrier particles.  
The drug molecules are shown as hexagons 
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3. PHAGE PROTEINS IN LIPOSOMES 
 
The ability of the major coat protein pVIII to form 
micelles and liposomes emerges from its intrinsic 
function as membrane protein judged by its biological, 
chemical, and structural properties. During infection of 
the host Escherichia coli, the phage coat is dissolved in 
the bacterial cytoplasmic membrane, while viral DNA 
enters the cytoplasm [12]. The protein is synthesized in 
infected cell as a water-soluble precursor, which contains 
a leader sequence of 23 residues at its N-terminus. When 
this protein is inserted into the membrane, the leader 
sequence is cleaved off by a leader peptidase. Later, 
during the phage assembly, the processed pVIII proteins 
are transferred from the membrane into a coat of the 
emerging phage. Thus, the major coat protein can change 
its conformation to accommodate to various distinctly 
different forms of the phage and its precursors: phage 
filament, intermediate particle (I-form), spheroid (S-
form), and membrane-bound form. This structural 
flexibility of the major coat protein is determined by its 
unique architecture, which is studied in much detail [17]. 
In virions, mostly α-helical domain of pVIII are arranged 
in layers with a 5-fold rotational symmetry and 
approximate 2-fold screw symmetry around the filament 
axis, as shown on the Fig. 3, right. In opposite, in the 
membrane-bound form of fd coat protein, the 16-Å-long 
amphipathic helix (residues 8-18) rests on the membrane 
surface, while the 35-Å-long trans-membrane (TM) helix 
(residues 21-45) crosses the membrane at an angle of 26o 
up to residue Lys40, where the helix tilt changes, as 
illustrated by Fig. 4.  The helix tilt accommodates the 
thickness of the phospholipid bilayer, which is 31 Å for 
E. coli membrane components. Tyr 21 and Phe 45 at the 
lipid–water interfaces delimit the TM helix, while a half 
of N-terminal and the last C-terminal amino acids, 
including the charged lysine side chains, emerge from the 
membrane interior. The transmembrane and amphipathic 
helices are connected by a short turn (Thr 19–Glu 20) that 
differs from the longer hinge loop (residues 17–26).  
N-Terminus
Phospholipid 
bilayer
Trans-membrane 
helix
Amphipathic helix
C-terminus
 
4. TARGETING OF THE ANTICANCER DRUG 
DOXIL BY THE STRIPPED LANDSCAPE PHAGE  
 
4.1. Stripped phage proteins 
 
In model experiments, landscape phages were converted 
to a new biorecognition affinity reagent — “stripped 
phage” [8]. The stripped phage is a composition of 
disassembled phage coat proteins with dominated (98%) 
recombinant major coat protein pVIII, which is 
genetically fused to the foreign target-binding peptides. 
The stripped phage proteins can form bioselective 
vesicles decorated by target-binding peptides, which can 
be used for the targeted drug delivery. In our example, the 
stripped phages were prepared by treatment of the 
landscape phages with chloroform (Fig. 5) followed by 
conversion of resulted spheroids into the lipid vesicles by 
their reconstruction with phospholipids. In preliminary 
experiments with streptavidin- and bacterial binders it 
was demonstrated by competition ELISA, acoustic wave 
sensor and transmission electron microscopy  that the 
stripped phage proteins retain the target-binding 
properties of the selected phage[8, 54].  
Fig. 4.  The model of the pVIII 
protein in the lipid environment 
(adapted from Stopar et al. 
2003).  
Fig. 5.  Transmission electron 
microscopy of landscape 
phage converted to spheroids.  
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4.2. Fusion of the stripped phage proteins with Doxil 
 
Using intrinsic mechanism of fusion of the phage proteins 
with lipid membranes, we incorporated streptavidin-
targeted proteins into the commercially available Doxil 
liposomes. The streptavidin-binding landscape phage was 
affinity selected from 9-mer landscape library. The phage 
was converted into spheroids with chloroform and 
incubated with Doxil to allow fusion of the phage 
proteins with liposome membrane, as illustrated by Fig. 
1. As a result of the phage fusion, the liposome acquired a 
new emergent property—ability to bind streptavidin and 
streptavidin-conjugated fluorescent molecules, as was 
evidenced by protein microarrays, fluorescent microscopy 
and fluorescence-activated cell sorting (FACS). The 
targeted and control liposomes were incubated with 
streptavidin-coated chips, washed and scanned (Fig. 6), 
or mixed with Texas Red-conjugated streptavidin (TRS), 
washed and analyzed by fluorescent microscopy and 
FACS. Complex of the modified Doxil with the target 
streptavidin demonstrated 50-fold higher fluorescence 
than pure Doxil and 10-fold higher fluorescence than 
control Doxil treated with TRS, as registered by FL6 
channel specific for fluorescence of the Texas Red label 
(data are not shown). No significant changes of 
fluorescent signals were registered in the FL2 channel, 
more specific for doxorubicin. Complex of the targeted 
Doxil liposomes with streptavidin-coated gold beads was 
visualized by transmission electron microscopy (Fig. 7).  
.  
5. CONCLUSION. LANDSCAPE PHAGE AS 
BIOSELECTIVE VEHICLE FOR TARGETED 
DRUG DELIVER 
 
We proved a novel approach for specific targeting of 
pharmaceutical nanocarriers through their fusion with 
stripped proteins of the affinity selected landscape phage. 
The phage specific for the target organ, tissue or cell is 
selected from the multibillion landscape phage libraries, 
and is combined with liposomes exploring intrinsic 
amphiphilic properties of the phage proteins. As a result, 
the targeting probe—the target-specific peptide fused to 
the major coat protein—is exposed on the shell of the 
drug-loaded vesicle. In contrast to sophisticated and 
poorly controllable conjugation procedures used for 
coupling of synthetic peptides and antibodies to the 
targeted vesicles, the new phage-based concept relies on 
very powerful and extremely precise mechanisms of 
selection, biosynthesis and self assembly. When 
landscape phage serve as a reservoir of the targeted 
membrane proteins, one of the most troublesome steps of 
the conjugation technology is bypassed. Furthermore, it 
does not require idiosyncratic reactions with any new 
shell-decorating polymer or targeting ligand and may be 
easily adapted to a new liposome or micelle composition 
and a new addressed target. No reengineering of the 
selected phage is required at all: the phages themselves 
serve as the source of the final product—coat protein 
genetically fused to the targeting peptide. A culture of 
phage-secreting cells is an efficient, convenient and 
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Fig. 6.  Microarray test for Doxil targeting. 
Streptavidin-microarrayed slide was treated with 
unmodified Doxil (1), Doxil modified with wild-
type phage (2) and Doxil targeted with 
streptavidin binding phage (3). 
A B 
Fig. 7. Transmission electron 
microscopy of original Doxil 
liposomes (A), and complexes of 
the targeted Doxil liposomes with 
streptavidin-coated 20 nm gold 
beads.  An evarage size of 
unmodified Doxil particals – 80 nm.  
©TIMA Editions/ENS 2006 -page- ISBN:  
Valery A. Petrenko, Sergey N. Ustinov, and I-Hsuan Chen  
Fusion Phage as a Bioselective Nanomaterial: Evolution of The Concept 
 
discontinuous protein production system. They are 
secreted from the cell nearly free of intracellular 
components; their further purification could be easily 
accomplished by simple steps that do not differ from one 
clone to another. The major coat protein constitutes 98% 
of the total protein mass of the virion — the purity hardly 
reachable in normal synthetic and bioengineering 
procedures. As a normal intestinal parasite, phage itself 
and its components are not toxic and have been already 
tested for safety in preclinical and clinical trials [51, 55]. 
In contrast to immunization procedure, the phage 
selection protocol may require tiny amounts of a target 
material (thousands of tumor cells available in biopsy 
procedure [42] for obtaining the tumor-specific phage 
ligands, affinity and selectivity of which may be 
controlled by exploring well developed depletion and 
affinity maturation procedures.   
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